Session(s)
- Single Inhaler Extrafine Triple Therapy Reduces Clinically Important Deterioration (CID) i...
Sunday, May 20 10:15 AM - 10:30 AM - Single Inhaler Triple-Therapy (ICS/LAMA/LABA) Versus Dual-Therapy (ICS/LABA or LAMA/LABA) ...
Sunday, May 20 10:30 AM - 10:45 AM - Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Du...
Sunday, May 20 10:45 AM - 11:00 AM - A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial of AZD8871, a Novel Dual-Act...
Monday, May 21 9:15 AM - 9:30 AM - Efficacy of Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone by Gender in Patients...
Monday, May 21 11:15 AM - 1:00 PM - Extrafine Formulation of Beclometasone Dipropionate, Formoterol Fumarate, Glycopyrronium (...
Monday, May 21 11:15 AM - 1:00 PM - Reduction in Fatal Events with ICS-containing Medications: Results of Safety Pooled Analys...
Monday, May 21 11:15 AM - 1:00 PM - Risk of Pneumonia and Exacerbations with Single Inhaler Extrafine Triple Therapy Compared ...
Monday, May 21 11:15 AM - 1:00 PM - Single Inhaler Extrafine Triple Therapy Improves Clinical Outcomes in Gold B COPD Patients...
Monday, May 21 11:15 AM - 1:00 PM - Single Inhaler Extrafine Triple Therapy Vs Indacaterol/Glycopyrronium in COPD Patients Pre...
Monday, May 21 11:15 AM - 1:00 PM - Validating Remote FEV1 Monitoring in Moderate Asthmatics to Increase Study Power [Board No...
Monday, May 21 11:15 AM - 1:00 PM - A Composite Endpoint of Clinically Important Deterioration in Chronic Obstructive Pulmonar...
Monday, May 21 2:15 PM - 4:15 PM - RPL554, A First-In-Class Dual PDE3/4 Inhibitor, Causes Rapid Additional Bronchodilation Wh...
Monday, May 21 2:15 PM - 4:15 PM - Single Inhaler Extrafine Triple Therapy Improves Quality of Life in COPD Patients Compared...
Monday, May 21 2:15 PM - 4:15 PM - An ‘Omics’ Study to Investigate the Mechanisms Underlying Circadian Rhythm in Asthma [Boar...
Tuesday, May 22 2:15 PM - 4:15 PM